Page 34 - CIBERER2016-ENG

CIBERER BIOBANK
Objective 1: To supply the Biobank with biological samples
The total number of samples of RD collected at the end of 2016 was over 600, of more than 70 different pathologies (http://www.ciberer-biobank.es).
Objective 2: To further the Plan for Strategic Alliances and Dissemination
COLLABORATION:
• Member of the Red Valenciana de Biobancos (RVB) since 2010, taking an active part in the different work groups.
• Cooperation Agreement with the Biobanco de Investigación Biomédica y Salud Pública de FISABIO.
• Framework agreement with the National DNA Bank.
• Biobank cooperating with the Red Nacional de Biobancos (RNB) of the ISCIII since 2010, and a member of the Haematic Derivatives Work Group.
• Agreement with the Fundación FEDER for contracting technical staff for supporting the development of the technique for generating human iPS.
• Cooperation agreement between the Institut d’Investigació Biomédica de Bellvitge, the Universidade de Vigo and the CIBERER for implementing the REWBA Registry.
• Contract with ABF Pharmaceutical Services GmbH for taking part in a clinical trial promoted by Boehringer Ingelheim Pharma GmbH & Co.
• Cooperation with the RNB and the Universidad Católica de Valencia in the University Master course on Biobanks.
MEASURES FOR DISSEMINATION OF THE WORK DONE BY THE BIOBANK
I Congreso de Investigación Traslacional de ER de la Comunidad Valenciana (oral presentation, OP), 9th Annual CIBERER Meeting (OP); OP of the biobank for medicine students, FISABIO; VII Congreso de la Red Nacional de Biobancos; Simposium Internacional de Plataformas de ER de la Fundación Ramón Areces- CIBERER.
Objective 3: To generate added value for CIBERER groups
SERVICES RENDERED
• Preparing and offering new services: keeping samples, establishing cell cultures and generation of lymphoblastoid lines, techniques for quality control of the samples.
• Work has continued to be done in the development of other services (culture of myoblasts, technique for immortalising fibroblasts at the request of several CIBERER groups and generation of iPS cells).
• In 2016 there were 12 assignments and 21 services provided for processing and safekeeping samples, establishment of cell cultures, cell immortalisation and advice for CIBERER groups.
Objective 4: To foster and support new lines of action in rare diseases
PARTICIPATION IN PROJECTS:
• FP7 HEALTH 2012-INNOVATION: RD-Connect: An integrated platform connecting registries, biobanks and clinical bioinformatics for RD.
• Participation, along with the U730 CIBERER group, in an international project for studying the Wolfram Syndrome, assuming responsibility for management of samples and immortalisation of lymphoblastoid lines.
• Spanish Exomes Project, SPANEX. A project financed with CIBERER funds in which it takes part along with 9 CIBERER groups by giving logistics support for collecting and storing samples, as well as advice on ethical/legal aspects.
• New diagnostic approaches for hereditary syndromes with bone medulla failure for treatment with innovative therapies (SHIMO) PI: Julián Sevilla (GCV19). Groups taking part: U710 (Dr. Bueren), U745 (Dr. Surallés); U753 (Dr. Lapunzina), U757 (Dr. Perona); GCV16-19.
• Induced pluripotent stem cells for modelling Charcot-Marie-Tooth disease. PI: Dr. Torres (U. Valencia). IP: Dr. Torres (U. Valencia).
13243